GHRP-6 is a synthetic hexapeptide growth hormone secretagogue: it prompts the pituitary to release its own stored growth hormone by binding the ghrelin receptor, rather than supplying growth hormone directly. It is not an FDA-approved drug and circulates in the US as a Research Use Only compound, and its defining trait is a pronounced increase in hunger.
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue that binds the GHSR-1a ghrelin receptor to trigger pituitary growth hormone release, and it is not approved as a medicine in any major jurisdiction.
GHRP-6 imitates ghrelin, the stomach-derived hunger hormone, at the GHSR-1a receptor that ghrelin itself uses. Activating that receptor on the anterior pituitary and hypothalamus triggers a pulse of growth hormone through two cooperating actions rather than a single fixed external dose.
GHRP-6 raises growth hormone through a dual mechanism, directly stimulating pituitary somatotrophs while increasing GHRH and suppressing somatostatin, producing a release pattern closer to the body's own pulsatile rhythm than recombinant growth hormone.
The regulatory answer is unambiguous: GHRP-6 is not an approved drug anywhere. It circulates as a research chemical labeled "for research use only," a legal boundary that shifts liability onto how the product is marketed and used rather than scheduling the molecule itself as a controlled substance in most jurisdictions.
No major regulatory agency has approved GHRP-6 for any human use, and it is sold as a Research Use Only chemical while remaining banned in competitive sport by the World Anti-Doping Agency at all times.
Most serious scientific work on GHRP-6 treated it as a tool for probing the growth hormone axis, not a finished therapy. The research record separates cleanly by evidence strength, and a large share of real-world use falls outside any research framework entirely.
GHRP-6's most cited research interest is its powerful appetite stimulation for wasting conditions such as cachexia, but its documented history is investigational and diagnostic, never advancing to an approved therapy for any condition.
The most honest statement about GHRP-6's safety is that its long-term risk profile in humans is not well established, and that uncertainty is itself the central concern. The reported effects come from limited data and anecdote, not from the controlled human safety trials an approved drug undergoes.
GHRP-6 has never undergone the controlled human safety trials an approved drug requires, so its documented effects (hunger, water retention, raised cortisol and prolactin, plus unregulated purity) represent an unquantified rather than a measured hazard.
GHRP-6 sits within the ghrelin-mimetic GHRP group alongside GHRP-2 and hexarelin, while GHRH analogs like sermorelin and CJC-1295 act on a different receptor entirely. Its signature trait, the strongest hunger response in the group, is both its research appeal for wasting conditions and the reason many prefer a more selective peptide.
| Criteria | GHRP-6 | GHRP-2 | Ipamorelin |
|---|---|---|---|
| GH pulse | Moderate | Somewhat stronger | Moderate, selective |
| Appetite effect | Strongest in class | Milder | Minimal |
| Cortisol / prolactin | Can raise | Some rise | Minimal |
Among the GHRPs, GHRP-6 produces the strongest appetite stimulation, GHRP-2 delivers a somewhat stronger growth hormone pulse with less hunger, and ipamorelin is the most selective with minimal effect on appetite, cortisol, or prolactin.
Because GHRP-6 is not an approved medicine, no official human dosing protocol exists, and what circulates mixes early clinical study parameters with unverified community practice. The published handling notes below are documentation of what the record reports, not validated dosing guidance.
No standardized human dosing protocol for GHRP-6 exists; published parameters describe subcutaneous or intravenous injection of a reconstituted lyophilized powder, and any figures circulating online carry the compound's unregulated purity uncertainty and were never set through dose-ranging safety trials.
GHRP-6's powerful appetite effect is a direct consequence of what it imitates. Ghrelin, the stomach's hunger hormone, drives eating through the hypothalamus and reward circuits, and GHRP-6 binds the same GHSR-1a receptor potently enough that reported hunger arrives within roughly twenty to forty minutes of a dose.
GHRP-6 stimulates hunger because it activates the same GHSR-1a receptor as ghrelin, producing a strong appetite surge reported within roughly twenty to forty minutes of a dose, the same trait that makes it of interest for cachexia and a drawback when only growth hormone release is wanted.
The clinical evidence base for GHRP-6 is real but limited, older, and never carried across the finish line to drug approval. The strongest human data are decades old and were built to understand a mechanism, not to prove a therapy, which leaves a wide gap between that record and the claims made for its marketed uses.
The credible evidence for GHRP-6 comes from late-1980s and 1990s clinical pharmacology studies proving it releases pituitary growth hormone, with broader benefit claims resting on preclinical work and no modern controlled human trials supporting its marketed physique or anti-aging uses.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-6. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
